Through the Simultaneous Merger of Six Companies, Ronin Helps Create the Only End-to-End Provider of Craft Brewery & Beverage Equipment in North America
20.4.2023 14:30:00 EEST | Business Wire | Press release
Operationally-focused buyout group, Ronin Equity Partners, has created Lotus Beverage Alliance through the simultaneous merger of six companies. The new group has 75 years of combined experience with locations in Lincoln, Nebraska, Ypsilanti, Michigan, Denver, Colorado, Portland, Oregon, and Hopewell Junction, New York. Lotus is a partnership of Alpha Brewing Operations, GW Kent, Twin Monkeys, Stout Tanks and Kettles, Brewmation and Automated Extractions.
Lotus’ more than 1,500 products and services - some patented and many customized - cover canning systems, automation and control systems, turn-key brewhouse construction, packaging, thermal processes, tanks and sanitation equipment. With a recurring spare parts business across all product lines, Lotus is the only company in North America to cover every step of craft brewery and beverage production, from raw ingredient supply to canning and other forms of packaging. In another first, Lotus has introduced a proprietary financing program that offers customers affordable financing options for all the company’s product lines. To provide, clients with maximum flexibility, credit approvals typically take less than 24 hours.
Ronin owns the majority of Lotus, and together, the six companies have a combined value of $100 million. Founders and management hold a significant double-digit ownership percentage, and Ronin has implemented an equity incentive program throughout the organization, extending to even the most junior employees. Research has shown that broad-based employee ownership programs improve worker retention, reduce income disparity, and result in higher margins, as well as improved growth and operating efficiencies across various aspects of a business. Ronin collaborated with Ownership Works in this employee ownership program’s creation.
“As the industry’s only one-stop shop, Lotus has everything that craft beverage creators need to produce the products they love, for the people who love them,” says John Ansbro, Lotus’ newly appointed CEO. “Our ownership structure makes us even more responsive to clients.”
Ansbro, an industry veteran with over 30 years of experience in equipment manufacturing (holding senior executive positions at Alfa Laval, Johnson Controls and the GEA Group) will be joined by Ronin Managing Partner and co-founder Jesse Yao, who will embed as Lotus’ CFO. Ronin Vice-President Jack Burke and Associate Elliott Rogasik are also taking senior executive positions. The board includes six Ronin operating advisors with experience running global operations at some of the world’s largest (or most celebrated) beer, food and beverage manufacturers, including SABMiller, AB InBev, Harpoon Brewery, KraftHeinz, Naked Juice and Ocean Spray).
“We are thrilled at the prospect of uniting a fragmented craft beverage supply landscape through a remarkable alliance of industry partners.” says Yao. “By embedding Ronin executives in the back office, our corporate partners can concentrate more fully on expanding their product range and increasing sales.” Managers and founders from the six merged companies form the bulk of senior management at Lotus.
On a combined basis, sales for the merged group rose 29 percent over three years to $65 million in 2022 while earnings before interest, tax, depreciation and amortization increased 39 percent. Rapidly growing international sales in Europe and Asia where high-quality, smaller-batch craft beer production is just taking off, accounts for some 7 percent of combined group sales, increasing from virtually nothing in 2019.
Beyond the purchase price, Ronin has reserved nearly $35 million in pre-arranged financing to fund acquisitions for Lotus in the Americas, Europe and Asia. Ronin and Lotus have identified more than 50 potential acquisitions and are in active discussions with nine of those companies.
In addition to craft beer, Lotus’ products and services are equally suited to other fast growing beverage markets including kombucha, cold brew coffee, hard seltzer, ready-to-drink cocktails, premium wines and ciders, and cannabis-infused drinks. These products currently account for some 26 percent of sales.
The six acquisitions forming Lotus were financed using Ronin’s balance sheet, with investments from a range of limited partners, including Nicola Wealth and Fiera Comox.
Since the first quarter of 2021, when it began investing, Ronin has deployed over $350 million including reserves for follow-on portfolio investment. The capital was committed to five platform investments, comprising a total of 21 companies. Since deal close - i.e. within two years - annualized earnings before interest, taxes, depreciation and amortization at Ronin’s first four platform companies have risen 30 percent to $104 million, while annualized revenues are up 23 percent to $484 million.
Triago Americas Inc., acted as sole placement agent on all of Ronin’s platform investments, including the Lotus transaction. Katten Muchin Rosenman acted as Ronin’s legal advisor on Lotus; buyside M&A advisors were KeyBanc and Harvey & Company. Debt was provided by Webster Bank as Lead Left Bookrunner & Administrative Agent and by Texas Capital Bank, BHI and Stifel Bank as Joint Lead Arrangers.
About Ronin Equity Partners
Based in New York City, Ronin Equity Partners represents a new type of investment firm, powered by an operationally-focused value creation strategy. Ronin makes control equity investments exclusively in the Industrial and Consumer sectors, where the team has prior expertise. The group buys strong businesses with high demonstrated cash flows, where Ronin’s operating playbook adds value. The Ronin team embeds into each company as interim senior executives to build a robust back-office infrastructure capable of scaling the business for growth and seamlessly integrating acquisitions. This partnership empowers management to focus entirely on growing the business without being burdened by back-office operations. The firm was founded in 2019 by Managing Partners David Feierstein and Jesse Yao alongside other former senior executives from Kraft Heinz, NCR, and Diversey. The firm is supported by some 75 operating advisors in the consumer and industrials sectors. www.roninequitypartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005234/en/
Contact information
David Lanchner, dlanchner@yahoo.com, +33 (0)6 3343-5076
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
